Triple celebration at Novo Nordisk Foundation Cellerator

On 4 March Cellerator hosted an event to celebrate:

• The spin out from the Novo Nordisk Foundation
• The move to temporary offices at the DTU campus in Lyngby
• The tender material - locked basic design of the Cellerator facility – sent out to construction companies to bid for turnkey contract

Cellerator’s CEO Thomas H.R. Carlsen welcomed the guests. The three milestones which have been passed prove that the Cellerator is developing in the same way as the stem cells will do in the state-of-the-art cell therapy laboratories which have been designed. The organisation is now a separate company, fully owned by the Novo Nordisk Foundation. Cellerator will develop its own culture to support the open collaborative way of working and contributing to the cell therapy ecosystem.

The Cellerator team will continue to collaborate closely with colleagues at the Novo Nordisk Foundation HQ, to ensure efficient execution on the regenerative medicine strategy and maturation of the cell therapy ecosystem, which will be instrumental in driving groundbreaking advancements and fostering innovation within the field.

The temporary office building will host the Cellerator team and collaborators from the engineering and construction team through out the construction phase of the project. The team will follow the construction work closely in real time and see how the design is turned into a physical building with all the advanced utilities and clean room installations needed to support cell therapy process development and manufacturing from the fall of 2027, where the facility is handed over from the turnkey contractor to Cellerator.

The spin-out, the locked design and the move to DTU indicates that Cellerator has passed the early stage of development and is primed to develop further into a fully functional cell therapy development and manufacturing facility. Likewise, the stem cells will after the early stage of differentiation express certain markers verifying that they are on the track the right therapeutic cell type.